Phase III Trial of Pembrolizumab Plus Doxorubicin in Aggressive Sarcomas
A phase III trial is comparing immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) against chemotherapy alone in patients with metastatic or unresectable poorly differentiated sarcomas.